James W Findling, MD, FACP | Medical College of Wisconsin

James W. Findling, MD, FACP

Clinical Professor of Medicine and Surgery

view physician profile

Locations

Froedtert Hospital
Froedtert Menomonee Falls Hospital
Waukesha Memorial Hospital
St. Agnes Hospital
North Hills Health Center - Specialty Clinics

Specialties

Endocrinology

Languages

English

Contact Information

General Interests

Pituitary-Adrenal Disorders

Education

MD - Doctor of Medicine
FACP-Fellow of the American College of Physicians

Biography

Dr. James Findling is currently Clinical Professor of Medicine and Surgery at the Medical College of Wisconsin. He is a graduate of the University of Notre Dame and Northwestern University Medical School. He completed his internal medicine training at the Medical College of Wisconsin and his post-doctoral fellowship in Endocrinology and Metabolism at the University of California-San Francisco. He started his endocrinology practice at St. Luke's Medical Center in Milwaukee in 1982 and he started the Endocrine-Diabetes Center at St. Luke's in 1987. Dr. Findling joined the full-time faculty of the Medical College of Wisconsin in 2008.

He has over 100 publications and book chapters and is considered an international expert on clinical disorders of pituitary and adrenal function. He discovered the importance of inferior petrosal sinus sampling for the differential diagnosis of Cushing syndrome in the early 1980s and then introduced late-night salivary cortisol as a simple screening test for Cushing syndrome in the 1990s. He has served as visiting professor at many institutions including the Mayo Clinic, Massachusetts General Hospital, Johns Hopkins, and the Cleveland Clinic.

Education

BS, University of Notre Dame
MD, Northwestern University
Internal Medicine Residency, Medical College of Wisconsin Endocrinology
Fellowship, University of California-San Francisco

Leadership Positions

External

Member, Editorial Board, Journal of the Endocrine Society
Member, Board of Directors, Cushing's Support and Research Foundation

Research Interests

Diagnosis and management of Cushing syndrome and adrenal insufficiency
Evaluation of adrenal hypertension particularly primary aldosteronism
Assessment of adrenal nodular disease

Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.

(Reincke M, Albani A, Assie G, Bancos I, Brue T, Buchfelder M, Chabre O, Ceccato F, Daniele A, Detomas M, Di Dalmazi G, Elenkova A, Findling J, Grossman AB, Gomez-Sanchez CE, Heaney AP, Honegger J, Karavitaki N, Lacroix A, Laws ER, Losa M, Murakami M, Newell-Price J, Giraldi FP, Pérez-Rivas LG, Pivonello R, Rainey WE, Sbiera S, Schopohl J, Stratakis CA, Theodoropoulou M, van Rossum EFC, Valassi E, Zacharieva S, Rubinstein G, Ritzel K.) Eur J Endocrinol. 2021 Mar;184(3):P1-P16 PMID: 33444221 SCOPUS ID: 2-s2.0-85101102568 01/15/2021
Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic

(Yuen KCJ, Mortensen MJ, Azadi A, Fonkem E, Findling JW.) Endocrinology, Diabetes and Metabolism. 2021 SCOPUS ID: 2-s2.0-85102201015 01/01/2021
Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome.

(Kannankeril J, Carroll T, Findling JW, Javorsky B, Gunsolus IL, Phillips J, Raff H.) J Endocr Soc. 2020 Oct 01;4(10):bvaa107 PMID: 32935666 PMCID: PMC7480956 09/17/2020
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.

(Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK, LINC 3 investigators.) Lancet Diabetes Endocrinol. 2020 09;8(9):748-761 PMID: 32730798 SCOPUS ID: 2-s2.0-85089392530 07/31/2020
Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic.

(Yuen KCJ, Blevins LS Jr, Findling JW.) Endocr Pract. 2020 Aug;26(8):915-922 PMID: 33471683 PMCID: PMC7833469 SCOPUS ID: 2-s2.0-85100279923 01/21/2021
Response to Letter to the Editor: Assay-Specific Spurious ACTH Results Lead to Misdiagnosis, Unnecessary Testing, and Surgical Misadventure-A Case Series.

(Wissner Greene L, Geer EB, Page-Wilson G, Findling JW, Raff H.) J Endocr Soc. 2020 Feb 01;4(2):bvz012 PMID: 32099949 PMCID: PMC7033035 02/27/2020
A commentary on Diagnosing Cushing's disease in the context of renal failure.

(Raff H, Cohen EP, Findling JW.) Eur J Endocrinol. 2019 Oct;181(4):C9-C11 PMID: 31349218 SCOPUS ID: 2-s2.0-85072229843 07/28/2019
Assay-Specific Spurious ACTH Results Lead to Misdiagnosis, Unnecessary Testing, and Surgical Misadventure-A Case Series.

(Greene LW, Geer EB, Page-Wilson G, Findling JW, Raff H.) J Endocr Soc. 2019 Apr 01;3(4):763-772 PMID: 30963134 PMCID: PMC6446888 04/10/2019
Mifepristone increases thyroid hormone requirements in patients with central hypothyroidism: A multicenter study

(Guarda FJ, Findling J, Yuen KCJ, Fleseriu M, Nachtigall LB.) Journal of the Endocrine Society. 2019;3(9):1707-1714 SCOPUS ID: 2-s2.0-85086582490 01/01/2019
Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol.

(Carroll TB, Peppard WJ, Herrmann DJ, Javorsky BR, Wang TS, Patel H, Zarnecki K, Findling JW.) J Endocr Soc. 2019 Jan 01;3(1):1-12 PMID: 30560224 PMCID: PMC6291660 12/19/2018
Differentiation of pathologic/neoplastic hypercortisolism (Cushing syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as Pseudo-Cushing syndrome): response to Letter to the Editor.

(Findling JW, Raff H.) Eur J Endocrinol. 2018 03;178(3):L3 PMID: 29440268 SCOPUS ID: 2-s2.0-85044408048 02/15/2018
Diagnosis and management of adrenal insufficiency

(He X, Findling JW, Auchus RJ.) Contemporary Endocrinology. 2018:199-215 SCOPUS ID: 2-s2.0-85065831062 01/01/2018